Probucol in the long-term treatment of hypercholesterolaemia

Publisher Website
Google Scholar
Abstract
SummaryA new hypocholesterolaemic drug, probucol, was effective in reducing mean serum cholesterol level in 52 patients by 17% after 3 months of treatment, and in 44 patients by 23% after one year of therapy. The level of baseline serum triglyceride did not significantly affect the cholesterol-lowering response. There was no significant difference in serum triglyceride response between patients on placebo and those on probucol. Except for one patient who exhibited a hypersensitivity reaction, the drug was well tolerated.